Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Torrential rains leave 25 dead in Brazil, dozens missing
-
Northeast US faces power cuts and school closures after snowstorm
-
US abstains in UN vote voicing support for Ukraine
-
Lebanon fears Israeli strikes if Iran situation escalates
-
Trump seeks to strike back in crucial State of the Union
-
World-class Brook played 'the best innings of his life' - Afridi
-
US appeals WTO ruling in dispute by China over clean energy subsidies
-
Guadalajara: World Cup host city rocked by narco violence
-
Briiliant Brook 100 puts England into T20 World Cup semi-finals
-
Germany's Merz heads to China for talks centred on trade
-
Briiliant Brook 100 puts England into T20 World Cups semi-finals
-
Warner Bros. 'reviewing' new takeover bid from Paramount
-
US told EU it 'stands' by tariff deal: trade chief
-
Torrential rains leave 23 dead in Brazil, dozens missing
-
UK govt says will release files on 'rude' ex-prince Andrew
-
Nearly an own gull! CPR performed on bird at Turkey football match
-
How AFP has used data analysis to cover the Ukraine war
-
Paris says US envoy pledges not to 'interfere' in France affairs
-
Post-it maker 3M on trial in Belgium over 'forever' chemicals
-
Iran says students must respect 'red lines' after protests
-
Italian biathlete Giacomel has heart surgery after Olympic withdrawal
-
Gazans salvage ancient books in mosque library damaged by war
-
Farhan scores 63 as England restrict Pakistan to 164-9
-
Stocks bounce as traders assess AI fallout, tariffs
-
Brazil court tries politicians over hit on Black councilwoman
-
Senegal PM vows to double penalty for same-sex relations
-
UK govt backs releasing documents tied to 'rude' ex-prince Andrew
-
Novo Nordisk to slash prices of weightloss drugs in US
-
Welllage says Sri Lanka can rescue T20 World Cup campaign
-
UK's royal protection officers urged to speak up in Epstein probe
-
Aid groups petition Israel's top court to halt ban on Gaza, West Bank ops
-
UEFA can make fight against racism more than a slogan: Real Madrid's Arbeloa
-
Bali flooding prompts tourist evacuation: official
-
Jones says Borthwick's 'title-decider' comments behind England collapse
-
UK fines Reddit nearly $20 mn over children's data failures
-
PSG star Hakimi faces trial for alleged rape
-
Netflix, Prime and Disney+ face UK broadcasting regulation
-
Greece set new tourism record in 2025
-
Zelensky says Ukraine unbroken after 4 years, but Russia vows to fight on
-
Zelenksy says Ukraine unbroken after 4 years, but Russia vows to fight on
-
Snoop Dogg 'can't wait' for first Swansea visit
-
Stocks fluctuate as traders assess AI fallout, tariffs
-
Post-it maker 3M faces Belgian trial over 'forever' chemicals
-
UK comedian Russell Brand pleads not guilty to new rape, assault charges
-
Duterte drew up 'death lists', boasted about murders: ICC prosecutor
-
UK govt urged to release documents linked to ex-prince Andrew
-
Rights group slams treatment of viral Japanese monkey
-
Inside the bunker where Zelensky led response to Russian invasion
-
France demands explanation from US envoy over 'surprise' no-show
-
Putin failed to achieve goals in Ukraine, Zelensky says on war anniversary
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
O.Salim--SF-PST